<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360996</url>
  </required_header>
  <id_info>
    <org_study_id>RP 11-003</org_study_id>
    <nct_id>NCT01360996</nct_id>
  </id_info>
  <brief_title>Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism</brief_title>
  <acronym>BEYAZ-PCOS</acronym>
  <official_title>Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Woman's</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The classic description of polycystic ovary syndrome (PCOS) is that it is a disorder
      characterized by menstrual irregularity, chronic anovulation, androgen excess, and abnormal
      gonadotropin secretion. Use of combined oral contraceptives (OCs) in women with PCOS
      effectively reduces circulating androgens. Although OCs are the most common and one of the
      oldest symptomatic treatment modalities for androgenic skin symptoms and for irregular
      menstrual cycles caused by hyperandrogenism, the data concerning the effect of treatment of
      PCOS women with different body mass index (BMI) are limited. This study is being done to
      compare the hormone and metabolic changes after treatment with low-dose oral birth control
      regimen of DRSP 3 mg/EE 0.02mg/levomefolate calcium 0.451 mg (Beyaz™) in women with PCOS with
      different body weights.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinically, polycystic ovary syndrome (PCOS) is a heterogeneous disorder of functional
      androgen excess and the features of PCOS can run through a spectrum of severity. The optimal
      modality for long-term treatment of PCOS should positively influence androgen synthesis, sex
      hormone binding globulin (SHBG) production, insulin sensitivity, the lipid profile, and
      clinical symptoms including hirsutism and irregular menstrual cycles. Combined oral
      contraceptives have been a key component of the chronic treatment of women with PCOS;
      improving androgen excess and regulating menstrual cycles. The effect of OCs on ovarian
      folliculogenesis significantly decreases androgen production. This mechanism was confirmed in
      both healthy women and women with PCOS. In obese patients with PCOS, it is likely that the
      suppression of androgen production is not as significant. It is thus possible to hypothesize
      that the effects of OCs in PCOS could be dependent on body weight and what is needed is a
      head-to-head comparison. The aim of this study is to compare the effect of 6 months of a
      low-dose oral contraceptive regimen of 24/4 DRSP 3 mg/EE 0.02mg/levomefolate calcium 0.451 mg
      on androgen profiles, cardiometabolic measures, B-vitamin status, and menstrual cycle
      regulation in three groups, normal (BMI 18-24.9 kg/ m2) overweight (BMI 25-29.9 kg/ m2) and
      obese (BMI 30-35 kg/ m2) women with PCOS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Assessment of Hyperandrogenism</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary outcome measure is post-treatment Free Androgen Index(FAI) which is expressed in units.
FAI is calculated by taking the testosterone concentration (in nmol/l) and dividing by concentration of sex hormone binding globulin (SHBG in nmol/L)and multiplying by 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic Measures</measure>
    <time_frame>24 weeks</time_frame>
    <description>Values represent blood pressure at 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Therapy BMI.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Post-treatment body mass index at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Indicator of B-vitamin Status</measure>
    <time_frame>24 weeks</time_frame>
    <description>Post-treatment in folate concentrations after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Cycle Regularity</measure>
    <time_frame>24 weeks</time_frame>
    <description>Post treatment menstrual frequency over 24 weeks normalized to number of menses per year ..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adrenal Androgen DHEAS</measure>
    <time_frame>24 weeks</time_frame>
    <description>Post-treatment levels of adrenal androgen DHEAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Disposition Index</measure>
    <time_frame>24 weeks</time_frame>
    <description>Post-treatment insulin secretion-sensitivity index (ISSI) calculated from the oral glucose tolerance test (OGTT). A higher value indicate improved carbohydrate metabolism</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>3 mg DRSP/20 μg EE--normal weight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
Normal weight -BMI 18-24.9 kg/ m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg DRSP/20 μg EE- Overweight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
BMI 25-29.9 kg/ m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg DRSP/20 μg EE- Grade 1 obese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
BMI 30-34.9 kg/ m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg DRSP/20 μg EE</intervention_name>
    <description>1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only</description>
    <arm_group_label>3 mg DRSP/20 μg EE--normal weight</arm_group_label>
    <arm_group_label>3 mg DRSP/20 μg EE- Overweight</arm_group_label>
    <arm_group_label>3 mg DRSP/20 μg EE- Grade 1 obese</arm_group_label>
    <other_name>folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive</other_name>
    <other_name>BeYaz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  •Adult female-16 years to 35 years of age who have been diagnosed with PCOS desiring
             contraception

               -  Actual BMI &gt;18 to &lt;35kg/ m2

               -  Written consent for participation in the study

               -  Patient completed lactation

        Exclusion Criteria:

          -  Metabolic abnormalities requiring pharmacological intervention (except controlled
             thyroid disease)

               -  Uncontrolled hypertension

               -  Cancer or history of hormone-dependent cancer

               -  History of cholestasis

               -  Presence of contradictions for OC administration

               -  Personal history of cardiovascular events.

               -  Use of drugs known to exacerbate glucose tolerance.

               -  No prescription or over-the-counter weight-loss drugs

               -  Diabetes

               -  Use of medications that affect blood pressure or lipid profile

               -  Smoking in past 6 months

               -  Known thrombogenic mutations (e.g. Factor V Leiden)

               -  Current or history of deep venous thrombosis/pulmonary embolism

               -  Major surgery with prolonged immobilization

               -  Injectable hormonal contraceptive use within 6 months

               -  Use of hormonal (e.g., oral contraceptive [OC] pill) or insulin-sensitizing
                  medication unless willing to cease medications for 3 months before study
                  measurements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen E Elkind-Hirsch, M.Sc.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Hospital, Louisiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha Paterson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Hospital Metabolic Health Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woman's Hospital</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <results_first_submitted>April 19, 2016</results_first_submitted>
  <results_first_submitted_qc>March 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2017</results_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's</investigator_affiliation>
    <investigator_full_name>Karen Elkind-Hirsch</investigator_full_name>
    <investigator_title>Scientific Director of Research</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This clinical trial was conducted from January 2012 to December 2014 Healthy, premenopausal women (n=64) with polycystic ovary syndrome (PCOS), aged between 16 and 35 years inclusive with a baseline body mass index (BMI) of &gt;18 to &lt;35kg/ m2, recruited from Woman’s Metabolic Health clinic and Woman’s Hospital gynecology clinics were enrolled</recruitment_details>
      <pre_assignment_details>Diabetic subjects, smokers, injectable hormonal contraceptive use within 6 months, or those taking sex hormones, carbohydrate metabolism, lipid-lowering and/or anti-obesity drugs within 3 months of the study were excluded</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>3 mg DRSP/20 μg EE--normal Weight</title>
          <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
Normal weight -BMI 18-24.9 kg/ m2
3 mg DRSP/20 μg EE: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only</description>
        </group>
        <group group_id="P2">
          <title>3 mg DRSP/20 μg EE- Overweight</title>
          <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
BMI 25-29.9 kg/ m2
3 mg DRSP/20 μg EE: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only</description>
        </group>
        <group group_id="P3">
          <title>3 mg DRSP/20 μg EE- Grade 1 Obese</title>
          <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
BMI 30-34.9 kg/ m2
3 mg DRSP/20 μg EE: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliant</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>oligomenorrhea and biochemical hyperandrogenism (total T &gt;1.38 nmol/l or free androgen index [FAI] &gt;3.87) and exclusion of other etiologies (non-classic congenital adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia, Cushing syndrome, thyroid dysfunction and primary ovarian insufficiency</population>
      <group_list>
        <group group_id="B1">
          <title>3 mg DRSP/20 μg EE--normal Weight</title>
          <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
Normal weight -BMI 18-24.9 kg/ m2
3 mg DRSP/20 μg EE: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only</description>
        </group>
        <group group_id="B2">
          <title>3 mg DRSP/20 μg EE- Overweight</title>
          <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
BMI 25-29.9 kg/ m2
3 mg DRSP/20 μg EE: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only</description>
        </group>
        <group group_id="B3">
          <title>3 mg DRSP/20 μg EE- Grade 1 Obese</title>
          <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
BMI 30-34.9 kg/ m2
3 mg DRSP/20 μg EE: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Healthy, premenopausal women (n=64) with polycystic ovary syndrome (PCOS), aged between 16 and 35 years inclusive with a body mass index (BMI) of &gt;18 to &lt;35kg/ m2,</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemical Assessment of Hyperandrogenism</title>
        <description>The primary outcome measure is post-treatment Free Androgen Index(FAI) which is expressed in units.
FAI is calculated by taking the testosterone concentration (in nmol/l) and dividing by concentration of sex hormone binding globulin (SHBG in nmol/L)and multiplying by 100</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Obese</title>
            <description>There was no significant difference on any variables between normal and overweight at baseline so groups were combined into non-obese
Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 18-29.9 kg/m2</description>
          </group>
          <group group_id="O2">
            <title>Obese</title>
            <description>Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 30-34.9 kg/m2 (obese grade 10</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Assessment of Hyperandrogenism</title>
          <description>The primary outcome measure is post-treatment Free Androgen Index(FAI) which is expressed in units.
FAI is calculated by taking the testosterone concentration (in nmol/l) and dividing by concentration of sex hormone binding globulin (SHBG in nmol/L)and multiplying by 100</description>
          <units>Index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.5"/>
                    <measurement group_id="O2" value="0.7" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiometabolic Measures</title>
        <description>Values represent blood pressure at 24 weeks.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Obese</title>
            <description>There was no significant difference on any variables between normal and overweight at baseline so groups were combined into non-obese
Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 18-29.9 kg/m2</description>
          </group>
          <group group_id="O2">
            <title>Obese</title>
            <description>Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 30-34.9 kg/m2 (obese grade 10</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiometabolic Measures</title>
          <description>Values represent blood pressure at 24 weeks.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="13"/>
                    <measurement group_id="O2" value="125" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Therapy BMI.</title>
        <description>Post-treatment body mass index at 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Obese</title>
            <description>There was no significant difference on any variables between normal and overweight at baseline so groups were combined into non-obese
Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 18-29.9 kg/m2</description>
          </group>
          <group group_id="O2">
            <title>Obese</title>
            <description>Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 30-34.9 kg/m2 (obese grade 10</description>
          </group>
        </group_list>
        <measure>
          <title>Post Therapy BMI.</title>
          <description>Post-treatment body mass index at 24 weeks</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="3.9"/>
                    <measurement group_id="O2" value="32.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Indicator of B-vitamin Status</title>
        <description>Post-treatment in folate concentrations after 24 weeks of treatment</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Obese</title>
            <description>There was no significant difference on any variables between normal and overweight at baseline so groups were combined into non-obese
Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 18-29.9 kg/m2</description>
          </group>
          <group group_id="O2">
            <title>Obese</title>
            <description>Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 30-34.9 kg/m2 (obese grade 10</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Indicator of B-vitamin Status</title>
          <description>Post-treatment in folate concentrations after 24 weeks of treatment</description>
          <units>Folate in nmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" spread="20.4"/>
                    <measurement group_id="O2" value="60.8" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Menstrual Cycle Regularity</title>
        <description>Post treatment menstrual frequency over 24 weeks normalized to number of menses per year ..</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Obese</title>
            <description>There was no significant difference on any variables between normal and overweight at baseline so groups were combined into non-obese
Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 18-29.9 kg/m2</description>
          </group>
          <group group_id="O2">
            <title>Obese</title>
            <description>Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 30-34.9 kg/m2 (obese grade 10</description>
          </group>
        </group_list>
        <measure>
          <title>Menstrual Cycle Regularity</title>
          <description>Post treatment menstrual frequency over 24 weeks normalized to number of menses per year ..</description>
          <units>number of cycles annually</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="1.7"/>
                    <measurement group_id="O2" value="11" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adrenal Androgen DHEAS</title>
        <description>Post-treatment levels of adrenal androgen DHEAS</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Obese</title>
            <description>There was no significant difference on any variables between normal and overweight at baseline so groups were combined into non-obese
Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 18-29.9 kg/m2</description>
          </group>
          <group group_id="O2">
            <title>Obese</title>
            <description>Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 30-34.9 kg/m2 (obese grade 10</description>
          </group>
        </group_list>
        <measure>
          <title>Adrenal Androgen DHEAS</title>
          <description>Post-treatment levels of adrenal androgen DHEAS</description>
          <units>micromol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="2.2"/>
                    <measurement group_id="O2" value="4.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Disposition Index</title>
        <description>Post-treatment insulin secretion-sensitivity index (ISSI) calculated from the oral glucose tolerance test (OGTT). A higher value indicate improved carbohydrate metabolism</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Obese</title>
            <description>There was no significant difference on any variables between normal and overweight at baseline so groups were combined into non-obese
Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 18-29.9 kg/m2</description>
          </group>
          <group group_id="O2">
            <title>Obese</title>
            <description>Folate-boosted 3 mg DRSP/20 ug EE-24/4 oral contraceptive
BMI 30-34.9 kg/m2 (obese grade 10</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Disposition Index</title>
          <description>Post-treatment insulin secretion-sensitivity index (ISSI) calculated from the oral glucose tolerance test (OGTT). A higher value indicate improved carbohydrate metabolism</description>
          <units>calculated index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="732" spread="420"/>
                    <measurement group_id="O2" value="272" spread="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.04</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>3 mg DRSP/20 μg EE--normal Weight</title>
          <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
Normal weight -BMI 18-24.9 kg/ m2
3 mg DRSP/20 μg EE: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only</description>
        </group>
        <group group_id="E2">
          <title>3 mg DRSP/20 μg EE- Overweight</title>
          <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
BMI 25-29.9 kg/ m2
3 mg DRSP/20 μg EE: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only</description>
        </group>
        <group group_id="E3">
          <title>3 mg DRSP/20 μg EE- Grade 1 Obese</title>
          <description>Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
BMI 30-34.9 kg/ m2
3 mg DRSP/20 μg EE: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations include evaluation after 24 weeks in a limited number of patients, The time may be too short and sample size too small to measure differences between normal and overweight PCOS women and the use of indirect measures of insulin action.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Karen Elkind-Hirsch</name_or_title>
      <organization>Woman's Hospital</organization>
      <phone>225-231-5275</phone>
      <email>karen.elkind-hirsch@womans.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

